New drug duo takes on tough breast cancer
NCT ID NCT07244874
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—Sacituzumab Tirumotecan and Toripalimab—as a first treatment for people with a specific type of advanced triple-negative breast cancer that is PD-L1 positive. The study aims to see if the combo shrinks tumors and improves survival. About 41 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan and toripalimab
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a hard-to-treat form of advanced breast cancer.
- What could go wrong
- This is a small, early-phase study with only 41 participants, so results may not apply to everyone. The combination may cause side effects or not improve outcomes enough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers